John Theo, Amarin

The FDA de­cides to hold an ex­pert pan­el re­view of Vas­cepa af­ter all — and Amarin shares tank on un­ex­pect­ed de­lay

Mark your cal­en­dars for No­vem­ber 14.

Af­ter slow­ly and cau­tious­ly rais­ing its hopes to the point where com­pa­ny ex­ecs be­lieved an Ad­Com on its sup­ple­men­tal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.